Schick C, Kamachi Y, Bartuski A J, Cataltepe S, Schechter N M, Pemberton P A, Silverman G A
Joint Program in Neonatology, Department of Pediatrics, Harvard Medical School, Children's Hospital, Boston, Massachusetts 02115-5737, USA.
J Biol Chem. 1997 Jan 17;272(3):1849-55. doi: 10.1074/jbc.272.3.1849.
The squamous cell carcinoma antigen (SCCA) serves as a serological marker for more advanced squamous cell tumors. Molecular cloning of the SCCA genomic region revealed the presence of two tandemly arrayed genes, SCCA1 and SCCA2. Analysis of the primary amino acid sequences shows that both genes are members of the high molecular weight serpin superfamily of serine proteinase inhibitors. Although SCCA1 and SCCA2 are nearly identical in primary structure, the reactive site loop of each inhibitor suggests that they may differ in their specificity for target proteinases. SCCA1 has been shown to be effective against papain-like cysteine proteinases. The purpose of this study was to determine whether SCCA2 inhibited a different family of proteolytic enzymes. Using recombinant DNA techniques, we prepared a fusion protein of glutathione S-transferase and full-length SCCA2 . The recombinant SCCA2 was most effective against two chymotrypsin-like proteinases from inflammatory cells, but was ineffective against papain-like cysteine proteinases. Serpin-like inhibition was observed for both human neutrophil cathepsin G and human mast cell chymase. The second order rate constants for these associations were on the order of approximately 1 x 10(5) M-1 s-1 and approximately 3 x 10(4) M-1 s-1 for cathepsin G and mast cell chymase, respectively. Moreover, SCCA2 formed SDS-stable complexes with these proteinases at a stoichiometry of near 1:1. These data showed that SCCA2 is a novel inhibitor of two physiologically important chymotrypsin-like serine proteinases.
鳞状细胞癌抗原(SCCA)是更晚期鳞状细胞肿瘤的血清学标志物。SCCA基因组区域的分子克隆揭示了两个串联排列的基因,即SCCA1和SCCA2的存在。对一级氨基酸序列的分析表明,这两个基因都是丝氨酸蛋白酶抑制剂的高分子量丝氨酸蛋白酶抑制剂超家族的成员。尽管SCCA1和SCCA2在一级结构上几乎相同,但每种抑制剂的反应位点环表明它们对靶蛋白酶的特异性可能不同。已证明SCCA1对木瓜蛋白酶样半胱氨酸蛋白酶有效。本研究的目的是确定SCCA2是否抑制不同的蛋白水解酶家族。使用重组DNA技术,我们制备了谷胱甘肽S-转移酶与全长SCCA2的融合蛋白。重组SCCA2对来自炎症细胞的两种胰凝乳蛋白酶样蛋白酶最有效,但对木瓜蛋白酶样半胱氨酸蛋白酶无效。在人中性粒细胞组织蛋白酶G和人肥大细胞糜酶中均观察到丝氨酸蛋白酶抑制剂样抑制作用。这些结合的二级速率常数对于组织蛋白酶G和肥大细胞糜酶分别约为1×10⁵ M⁻¹ s⁻¹和约3×10⁴ M⁻¹ s⁻¹。此外,SCCA2与这些蛋白酶以接近1:1的化学计量比形成SDS稳定的复合物。这些数据表明SCCA2是两种生理上重要的胰凝乳蛋白酶样丝氨酸蛋白酶的新型抑制剂。